Novartis (NVS) Pharmaceuticals’ iptacopan was granted FDA orphan designation as a treatment of myasthenia gravis, according to a post to the agency’s website.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Top drugmakers to enter agreements with U.S. to cut drug prices, Reuters says
- Avidity reports FTC granted request for early termination of HSR waiting period
- Salesforce’s Agentforce Life Sciences Gains Traction with Another Healthcare Provider Onboard
- Novartis, Roche nearing drug price deals with U.S., Bloomberg says
- Salesforce Agentforce Life Sciences selected by Novartis